Effects of short-term fructooligosaccharide intake on equol production in Japanese postmenopausal women consuming soy isoflavone supplements: a pilot study
BACKGROUND: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person’s ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in t...
Saved in:
| Published in | Nutrition journal Vol. 12; no. 1; pp. 127 - 705 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Springer-Verlag
13.09.2013
BioMed Central BioMed Central Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2891 1475-2891 |
| DOI | 10.1186/1475-2891-12-127 |
Cover
| Abstract | BACKGROUND: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person’s ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women. METHODS: A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period. RESULTS: The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios. CONCLUSIONS: We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. |
|---|---|
| AbstractList | Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women.
A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5 g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period.
The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios.
We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. BACKGROUND: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person’s ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women. METHODS: A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period. RESULTS: The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios. CONCLUSIONS: We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women. A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period. The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time x equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios. We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. Doc number: 127 Abstract Background: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women. Methods: A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period. Results: The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios. Conclusions: We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. Background Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person’s ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women. Methods A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period. Results The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios. Conclusions We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. Background Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women. Methods A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period. Results The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time x equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios. Conclusions We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. Keywords: Isoflavones, Equol, Fructooligosaccharides, Intestinal microbiota Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women.BACKGROUNDRecent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to produce equol from daidzein. Equol, which is a metabolite of one of the major soybean isoflavones called daidzein, is produced in the gastrointestinal tract by certain intestinal microbiota where present. Habitual dietary patterns may alter the intestinal bacterial profile, and influence the metabolism of isoflavones and the production of equol. Fructooligosaccharides (FOS) have a prebiotic activity as well as being a dietary fibre. The purpose of the present study was to determine whether FOS supplementation increases equol production in equol producers and stimulates equol production in equol non-producers in Japanese postmenopausal women.A soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5 g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period.METHODSA soy challenge was used to assess equol-producer status prior to the start of the study in healthy postmenopausal Japanese women. The study involved 4 separate groups in randomised crossover design. First, subjects were classified as equol producers (n = 25) or non-producers (n = 18), and then they were randomly assigned to the FOS or control group. All subjects received a daily dose of 37 mg isoflavone conjugates in the capsule (21 mg aglycone form) and either FOS (5 g/day) or sucrose as control, in a randomised crossover study design. Equol -production was assessed by testing the serum and urine before and after the 2-week supplementation period.The analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios.RESULTSThe analyses were conducted on 34 subjects completed the study, 21 (61.8%) were classified as equol producers, and 13 (38.2%) as non-producers. Significant differences were observed in the interaction effect of time × equol state after 1 week of intervention (p = 0.006). However there were no effects after 2 weeks of intervention (p = 0.516). Finally, in both equol producers and non-producers, FOS supplementation did not affect the serum equol concentration or the urinary equol to daidzein concentration ratios.We have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production.CONCLUSIONSWe have reported that FOS intervention (5 g/day for 2 weeks) does not significantly modulate the capacity of intestinal microbiota to produce equol in postmenopausal Japanese women, in either equol producers or non-producers in this pilot study. Further larger investigations that explore the roles of specific intestinal microbiota in equol production will enable the establishment of dietary conditions that are required to enhance equol production. |
| ArticleNumber | 127 |
| Audience | Academic |
| Author | Ishimi, Yoshiko Uehara, Mariko Kimira, Yoshifumi Tousen, Yuko Abe, Fumiko |
| AuthorAffiliation | 3 Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan 2 Department of Nutritional Science, Faculty of Applied Bio-Science, Tokyo University of Agriculture, 1-1-1 Sakuragaoka, Setagaya-ku, Tokyo 156-8502, Japan 1 Department of Food Function and Labeling, National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan |
| AuthorAffiliation_xml | – name: 2 Department of Nutritional Science, Faculty of Applied Bio-Science, Tokyo University of Agriculture, 1-1-1 Sakuragaoka, Setagaya-ku, Tokyo 156-8502, Japan – name: 1 Department of Food Function and Labeling, National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan – name: 3 Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan |
| Author_xml | – sequence: 1 fullname: Tousen, Yuko – sequence: 2 fullname: Uehara, Mariko – sequence: 3 fullname: Abe, Fumiko – sequence: 4 fullname: Kimira, Yoshifumi – sequence: 5 fullname: Ishimi, Yoshiko |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24034304$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktv1DAQxyNURB9w5wSWuMBhi99JOCBVVYGiSkiUni2vM0ldEju1nUI_C18WR1uW3YqHYuUx_v3Hk__MfrHjvIOieErwISGVfE14KRa0qsmC0LzKB8XeOrSz8b5b7Md4hTGtqrp8VOxSjhlnmO8VP07aFkyKyLcoXvqQFgnCgNowmeR9bzsftTGXOtgGkHVJfwXkHYLryfdoDL7JnM0B69BHPWoHEdDoYxrA-VFPUffom88fyHgXp8G6DkV_i2z0ba9v8t-gOI1jDxlJ8Q3SaLS9Tyimqbl9XDxsdR_hyd3zoLh4d_Ll-MPi7NP70-Ojs4WRNU6LRnPeyEoDaKBNbWgpiJSUCMAlAG25WFaatKKWDFNayaUsSS0FI0IIU0PDDoq3q7zjtBygMbmUoHs1BjvocKu8tmp7x9lL1fkbxSpeyUrmBC_vEgR_PUFMarDRQN9nP_wUVS6HScYxLv-PclETQUhJMvriHnrlp-CyE5liJauIYOw31ekelHWtzyWaOak6EoxLwSWdjz38A5WvBgabWwOtzfEtwastQWYSfE9dbmlUp-eft9lnm_6tjfs1ZRnAK8AEH2OAdo0QrOZBVvOkqnlSFaF5zTnlPYmxSc-jlgu3_b-EZCWM-QzXQdhw7e-a5ytNq73SXbBRXZxTTHLHCJ9v7CfsLw_w |
| CitedBy_id | crossref_primary_10_1016_j_foodres_2018_06_068 crossref_primary_10_1016_j_anaerobe_2024_102923 crossref_primary_10_1016_j_jff_2023_105784 crossref_primary_10_1039_D0FO03377D crossref_primary_10_1007_s00774_022_01375_x crossref_primary_10_1016_j_phanu_2016_02_003 crossref_primary_10_1088_1742_6596_1025_1_012061 crossref_primary_10_1016_j_jsbmb_2015_10_024 crossref_primary_10_1017_S0007114516001537 crossref_primary_10_3390_cells13131145 crossref_primary_10_1016_j_jep_2015_12_031 crossref_primary_10_3136_fstr_25_569 crossref_primary_10_1155_2021_6331630 crossref_primary_10_1002_vms3_450 crossref_primary_10_3390_antiox9100982 crossref_primary_10_3390_nu9030207 crossref_primary_10_1002_jsfa_13154 crossref_primary_10_1097_GME_0000000000001702 crossref_primary_10_3390_nu9030196 crossref_primary_10_1016_j_matpr_2022_03_549 crossref_primary_10_1007_s00394_017_1546_4 crossref_primary_10_1080_10408398_2022_2154744 |
| Cites_doi | 10.1016/j.nut.2007.06.010 10.1093/jn/136.5.1347 10.1210/jc.2008-0735 10.1016/S0887-2333(01)00048-0 10.1007/s00253-008-1719-4 10.3181/00379727-217-44241 10.1080/01635589609514485 10.1093/jn/134.8.1998 10.1016/j.mehy.2004.11.046 10.1038/sj.ejcn.1602910 10.1207/S15327914NC3601_5 10.1093/jn/136.8.2188 10.1158/1940-6207.CAPR-11-0251 10.1186/1475-2891-6-42 10.1177/153537020523000302 10.1002/mnfr.200600262 10.1093/jjco/hyh015 10.1093/jn/131.3.740 10.1007/s00284-011-9904-6 10.1016/j.jsbmb.2004.12.041 10.3177/jnsv.48.423 10.1016/S0039-128X(00)00089-1 10.1093/jn/132.12.3577 10.2188/jea.10.127 10.1093/jn/131.6.1826 10.1007/978-1-4613-0399-2_7 10.1124/mol.54.1.105 10.1038/sj.ejcn.1602509 10.1093/jn/132.7.2048 10.1080/01635580701525885 10.1023/A:1008968003575 10.1016/j.jsbmb.2006.06.020 10.1093/ajcn/54.6.1093 10.1038/sj.pcan.4501030 10.1186/1475-2891-5-8 10.1093/jn/135.6.1400 10.1016/S0960-0760(03)00071-2 |
| ContentType | Journal Article |
| Copyright | Tousen et al.; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. COPYRIGHT 2013 BioMed Central Ltd. 2013 Tousen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2013 Tousen et al.; licensee BioMed Central Ltd. 2013 Tousen et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Tousen et al.; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: COPYRIGHT 2013 BioMed Central Ltd. – notice: 2013 Tousen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright © 2013 Tousen et al.; licensee BioMed Central Ltd. 2013 Tousen et al.; licensee BioMed Central Ltd. |
| DBID | FBQ C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7QP 7RQ 7RV 7TS 7X7 7XB 88E 8C1 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M1P M2O MBDVC NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| DOI | 10.1186/1475-2891-12-127 |
| DatabaseName | AGRIS Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Career & Technical Education Database ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. Physical Education Index Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database ProQuest Research Library Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China Physical Education Index ProQuest Central ProQuest One Sustainability Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Career and Technical Education ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database AGRICOLA MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database – sequence: 5 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Diet & Clinical Nutrition Medicine Chemistry |
| EISSN | 1475-2891 |
| EndPage | 705 |
| ExternalDocumentID | PMC3848686 3084222171 A534654627 24034304 10_1186_1475_2891_12_127 US201400144001 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan United States |
| GeographicLocations_xml | – name: Japan – name: United States |
| GroupedDBID | --- -A0 04C 123 29N 2VQ 2WC 2XV 3V. 4.4 53G 5VS 7RQ 7RV 7X7 88E 8C1 8FI 8FJ 8G5 A8Z AAFWJ AAJSJ AAWTL ABDBF ABPTK ABUWG ABVAZ ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ AEAQA AENEX AFGXO AFKRA AFNRJ AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BKEYQ BMC BMSDO BPHCQ BVXVI C1A C24 C6C CCPQU CS3 DIK DU5 DWQXO E3Z EAD EAP EAS EBD EBS ECGQY EIHBH EJD EMB EMK EMOBN ESTFP ESX EX3 F5P FBQ FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 H13 HH5 HMCUK HYE IAO ICU ICW IHR IHT INH INR IPNFZ IPT ISE ISR ITC KQ8 M1P M2O M48 M~E NAPCQ O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO QF4 QN7 RBZ RIG RNS ROL RPM RSV SCM SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB 0R~ AAHBH AASML ACUHS ADUKV AEUYN EBLON OVT PGMZT PHGZM PHGZT PJZUB PPXIY PUEGO AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 7QP 7TS 7XB 8FK K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c690t-da44d68aeeae2d9c275166215e07ee2f45b8a1f596302286b67196531555c9ed3 |
| IEDL.DBID | M48 |
| ISSN | 1475-2891 |
| IngestDate | Thu Aug 21 18:11:33 EDT 2025 Fri Sep 05 13:37:46 EDT 2025 Fri Sep 05 04:28:15 EDT 2025 Fri Jul 25 06:12:45 EDT 2025 Tue Jun 17 22:04:48 EDT 2025 Tue Jun 10 21:00:54 EDT 2025 Fri Jun 27 05:44:26 EDT 2025 Mon Jul 21 05:51:04 EDT 2025 Thu Apr 24 22:59:27 EDT 2025 Tue Jul 01 03:09:34 EDT 2025 Sat Sep 06 07:30:16 EDT 2025 Wed Dec 27 18:56:37 EST 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Intestinal microbiota Equol Fructooligosaccharides Isoflavones |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c690t-da44d68aeeae2d9c275166215e07ee2f45b8a1f596302286b67196531555c9ed3 |
| Notes | http://dx.doi.org/10.1186/1475-2891-12-127 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1475-2891-12-127 |
| PMID | 24034304 |
| PQID | 1437381533 |
| PQPubID | 42849 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3848686 proquest_miscellaneous_1663634007 proquest_miscellaneous_1459151171 proquest_journals_1437381533 gale_infotracmisc_A534654627 gale_infotracacademiconefile_A534654627 gale_incontextgauss_ISR_A534654627 pubmed_primary_24034304 crossref_primary_10_1186_1475_2891_12_127 crossref_citationtrail_10_1186_1475_2891_12_127 springer_journals_10_1186_1475_2891_12_127 fao_agris_US201400144001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-09-13 |
| PublicationDateYYYYMMDD | 2013-09-13 |
| PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nutrition journal |
| PublicationTitleAbbrev | Nutr J |
| PublicationTitleAlternate | Nutr J |
| PublicationYear | 2013 |
| Publisher | Springer-Verlag BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: Springer-Verlag – name: BioMed Central – name: BioMed Central Ltd |
| References | Y Bouhnik (705_CR25) 2006; 5 LJ Lu (705_CR36) 1996; 26 M Tamura (705_CR22) 2011; 62 H Adlercreutz (705_CR33) 1991; 54 K Fujimoto (705_CR13) 2008; 11 JW Lampe (705_CR10) 1998; 217 A Ohta (705_CR39) 2002; 132 M Blaut (705_CR24) 2002; 41 JP Yuan (705_CR43) 2007; 51 Y Hata (705_CR40) 1985; 23 MF McCarty (705_CR4) 2006; 66 CS Hwang (705_CR5) 2006; 101 K Taku (705_CR7) 2010; 19 E Brouwers (705_CR32) 2003; 84 PL Horn-Ross (705_CR20) 2000; 11 E Schmitt (705_CR1) 2001; 15 TE Hedlund (705_CR17) 2005; 135 AA Mulligan (705_CR21) 2007; 61 705_CR41 IR Rowland (705_CR12) 2000; 36 TA Larkin (705_CR27) 2009; 63 S Barnes (705_CR35) 1996; 401 Y Bouhnik (705_CR38) 2007; 6 A Matsumura (705_CR2) 2005; 94 MH Richmond (705_CR30) 1977 SA Khan (705_CR8) 2012; 52 C Nagata (705_CR16) 2008; 60 MJ de Kleijn (705_CR19) 2001; 131 SB Levy (705_CR29) 1986 S Raimondi (705_CR23) 2009; 81 KD Setchell (705_CR34) 2006; 136 K Katanoda (705_CR18) 2002; 48 TA Larkin (705_CR28) 2007; 23 T Barkhem (705_CR3) 1998; 54 P Villa (705_CR6) 2009; 94 KD Setchell (705_CR9) 2002; 132 GJ Wang (705_CR31) 2000; 65 KB Song (705_CR37) 2006; 136 H Akaza (705_CR14) 2004; 34 Y Arai (705_CR15) 2000; 10 C Atkinson (705_CR11) 2005; 230 JA Nettleton (705_CR42) 2004; 134 JW Lampe (705_CR26) 2001; 131 |
| References_xml | – volume: 41 start-page: I11 issue: Suppl 1 year: 2002 ident: 705_CR24 publication-title: Eur J Nutr – volume: 23 start-page: 709 year: 2007 ident: 705_CR28 publication-title: Nutrition doi: 10.1016/j.nut.2007.06.010 – volume: 136 start-page: 1347 year: 2006 ident: 705_CR37 publication-title: J Nutr doi: 10.1093/jn/136.5.1347 – volume: 94 start-page: 552 year: 2009 ident: 705_CR6 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-0735 – start-page: 17 volume-title: Antibiotic resistance genes: Ecology, transfer and expression year: 1986 ident: 705_CR29 – volume: 15 start-page: 433 year: 2001 ident: 705_CR1 publication-title: Toxicol In Vitro doi: 10.1016/S0887-2333(01)00048-0 – volume: 81 start-page: 943 year: 2009 ident: 705_CR23 publication-title: Appl Microbiol Biotechnol doi: 10.1007/s00253-008-1719-4 – volume: 217 start-page: 335 year: 1998 ident: 705_CR10 publication-title: Proc Soc Exp Biol Med doi: 10.3181/00379727-217-44241 – volume: 26 start-page: 289 year: 1996 ident: 705_CR36 publication-title: Nutr Cancer doi: 10.1080/01635589609514485 – volume: 134 start-page: 1998 year: 2004 ident: 705_CR42 publication-title: J Nutr doi: 10.1093/jn/134.8.1998 – volume: 66 start-page: 1093 year: 2006 ident: 705_CR4 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2004.11.046 – volume: 63 start-page: 238 year: 2009 ident: 705_CR27 publication-title: Eur J Clin Nutr doi: 10.1038/sj.ejcn.1602910 – volume: 36 start-page: 27 year: 2000 ident: 705_CR12 publication-title: Nutr Cancer doi: 10.1207/S15327914NC3601_5 – volume: 136 start-page: 2188 year: 2006 ident: 705_CR34 publication-title: J Nutr doi: 10.1093/jn/136.8.2188 – volume: 52 start-page: 309 year: 2012 ident: 705_CR8 publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-11-0251 – volume: 6 start-page: 42 year: 2007 ident: 705_CR38 publication-title: Nutr J doi: 10.1186/1475-2891-6-42 – volume: 19 start-page: 33 year: 2010 ident: 705_CR7 publication-title: Asia Pac J Clin Nutr – volume: 230 start-page: 155 year: 2005 ident: 705_CR11 publication-title: Exp Biol Med doi: 10.1177/153537020523000302 – volume: 51 start-page: 765 year: 2007 ident: 705_CR43 publication-title: Mol Nutr Food Res doi: 10.1002/mnfr.200600262 – volume: 34 start-page: 86 year: 2004 ident: 705_CR14 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/hyh015 – volume: 131 start-page: 740 year: 2001 ident: 705_CR26 publication-title: J Nutr doi: 10.1093/jn/131.3.740 – volume: 62 start-page: 1632 year: 2011 ident: 705_CR22 publication-title: Curr Microbiol doi: 10.1007/s00284-011-9904-6 – volume: 94 start-page: 431 year: 2005 ident: 705_CR2 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2004.12.041 – volume: 48 start-page: 423 year: 2002 ident: 705_CR18 publication-title: J Nutr Sci Vitaminol doi: 10.3177/jnsv.48.423 – volume: 65 start-page: 339 year: 2000 ident: 705_CR31 publication-title: Steroids doi: 10.1016/S0039-128X(00)00089-1 – volume: 132 start-page: 3577 year: 2002 ident: 705_CR9 publication-title: J Nutr doi: 10.1093/jn/132.12.3577 – volume: 10 start-page: 127 year: 2000 ident: 705_CR15 publication-title: J Epidemiol doi: 10.2188/jea.10.127 – volume: 131 start-page: 1826 year: 2001 ident: 705_CR19 publication-title: J Nut doi: 10.1093/jn/131.6.1826 – volume: 401 start-page: 87 year: 1996 ident: 705_CR35 publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4613-0399-2_7 – volume: 54 start-page: 105 year: 1998 ident: 705_CR3 publication-title: Mol Pharmacol doi: 10.1124/mol.54.1.105 – volume: 61 start-page: 248 year: 2007 ident: 705_CR21 publication-title: Eur J Clin Nutr doi: 10.1038/sj.ejcn.1602509 – volume: 132 start-page: 2048 year: 2002 ident: 705_CR39 publication-title: J Nutr doi: 10.1093/jn/132.7.2048 – volume: 60 start-page: 49 year: 2008 ident: 705_CR16 publication-title: Nutr Cancer doi: 10.1080/01635580701525885 – ident: 705_CR41 – volume: 11 start-page: 299 year: 2000 ident: 705_CR20 publication-title: Cancer Causes Control doi: 10.1023/A:1008968003575 – volume: 101 start-page: 246 year: 2006 ident: 705_CR5 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2006.06.020 – volume: 54 start-page: 1093 year: 1991 ident: 705_CR33 publication-title: Am J Clin Nutr doi: 10.1093/ajcn/54.6.1093 – volume: 11 start-page: 252 year: 2008 ident: 705_CR13 publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/sj.pcan.4501030 – volume: 5 start-page: 8 year: 2006 ident: 705_CR25 publication-title: Nutr J doi: 10.1186/1475-2891-5-8 – volume: 135 start-page: 1400 year: 2005 ident: 705_CR17 publication-title: J Nutr doi: 10.1093/jn/135.6.1400 – start-page: 61 volume-title: Topics in infectious diseases year: 1977 ident: 705_CR30 – volume: 84 start-page: 577 year: 2003 ident: 705_CR32 publication-title: J Steroid Biochem Mol Biol doi: 10.1016/S0960-0760(03)00071-2 – volume: 23 start-page: 817 year: 1985 ident: 705_CR40 publication-title: Geriatr Med (in Japanese) |
| SSID | ssj0028897 |
| Score | 2.1440008 |
| Snippet | BACKGROUND: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person’s... Background Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person’s... Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's ability to... Background Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be attributed to a person's... Doc number: 127 Abstract Background: Recent studies suggest that some of the clinical effectiveness of soy or daidzein, which is a type of isoflavone, may be... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer fao |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 127 |
| SubjectTerms | beta-Glucans beta-Glucans - metabolism beta-Glucans - therapeutic use Biomarkers Biomarkers - blood Biomarkers - metabolism Biomarkers - urine blood blood serum Breast cancer chemistry Clinical Nutrition Computer software industry Cross-Over Studies daidzein Diet dietary fiber Dietary Supplements eating habits Equol Equol - blood Equol - metabolism Equol - urine experimental design Female Food Food and nutrition fructooligosaccharides gastrointestinal system Glycine max - chemistry Health aspects Health Promotion and Disease Prevention Humans intestinal microorganisms Intestinal Mucosa Intestinal Mucosa - microbiology Intestines Intestines - microbiology Isoflavones Isoflavones - metabolism Isoflavones - therapeutic use Isoflavones - urine Japan Japanese people Medicine Medicine & Public Health metabolism Metabolites Microbiology Microbiota (Symbiotic organisms) Middle Aged Nutrition research Oligosaccharides Oligosaccharides - metabolism Oligosaccharides - therapeutic use Osteoporosis, Postmenopausal Osteoporosis, Postmenopausal - metabolism Osteoporosis, Postmenopausal - microbiology Osteoporosis, Postmenopausal - prevention & control Physiological aspects Pilot Projects Postmenopausal women Postmenopause Prebiotics prevention & control Science Seeds Seeds - chemistry Soy products Soybean soybeans Soyfoods Studies sucrose therapeutic use urine Women Womens health |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELe27oUXBBuwjIEMQiCQojUfdhwkhApsGpOo0MakvVmJ7bQRIe5IirS_hX-WOzcp7RCVojzE5_jrfL6zz78j5EWQc1bEIvBBGzd-LBTIQaGUr3lYMFRRhQsG82XMTy_jsyt2tUXG_V0YdKvsZaIT1Noq3CM_ChwGD2on72fXPkaNwtPVPoRG1oVW0O8cxNg22QGRzIYDsvPhePz1fGmCCZEm_WGl4PDThEEt0wAdFFxkmZXFabvI7L-CemWluu1Feeso1a1QJ_fI3U61pKMFL9wnW6beJXujGszqHzf0JXXOnm4XfZd4n0rTwrcOFrSi4x6Vf4_8XiAaN9QWtJmCeu6j-KYFAs1aW5UT20BHTMHI1oaWdZt9N9TW1FzPbUVnCwRZ-BEk0TNYijHEJZ3ZBt3ZwUKfN1Caw32gyl3_hLbQxt7QsrFFlf2ytaENhhp1-5bNW5rRWVnZljog3Afk8uT428dTv4vh4Cuwu1tfZ3GsuciMyUyoUxUmLOAc9AwzTIwJi5jlIgsKBnIAkXh4zhPEOIxgGJlKjY4ekkENJe8TOtRJkehIsSjPYUllmRJagzkmihR0wJx75KgfPKk6gHOMs1FJZ-gILnG4JQ63DEJ4Eo-8XuaYLcA9NtDuAz_IbAKyV15ehGiZojUKL488RyaRCKdRo7_OBPqykZ8vzuWIRQhYxzH_q46osFArlXXXH6BtiMC1Rnm4RgnzXa0n97woO3nTyL-zwyPPlsmYE33oamPnSMNS0O-CJNhAAwooj6BRUMyjBXsvewaRG-NoGHskWWP8JQEila-n1OXUIZZHIhZcwAi96afIStX_0-EHm9v5mNwJXWSS1A-iQzJof87NE9AP2_xpN-n_APZFYwI priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Rb9MwELbYkBAvCDpggYEMQiCQotVJ7Di8VYVpTNoeGJX2ZjmO00WEuJAUab-FP8udm1bNgElIVR7qc2zH9vk7-_wdIa9YLniZSBYCGrdhIg3oQWlMWIio5AhRpQ8Gc3omjmfJyQW_6Pc78C7M9vk9k-KQJSmH92QMXQhYlO6Q2xzULo7lqZhuTCsps3R9CPmXXINFZ6fU7k8FvLUCXfeOvHZE6leeo_vkXg8Z6WTVxw_ILduMyN6kAXP52xV9Tb0Tp98dH5HgQ2U7-K-n-6zp2Zptf0TunPbn6Hvk14q0uKWupO0lIPAQNTQtkUvWubqau1YbvJBVFZZWTae_Wuoaar8vXU0XK5JYeCck0RNYbTGKJV24Fj3WwQhftlCwp3agxt_whGbR1l3RqnVlrX-6xtIWo4n6rcn2PdV0UdWuo57r9iGZHX38Mj0O-zANoQHTugsLnSSFkNpabaMiM1HKmRAAJew4tTYqE55LzUoOUx3JdkQuUqQxjAHJcJPZIn5EdhsoeZ_QcZGWaREbHuc5rJpcG1kUYHHJMgOYl4uAHK77UZmewxxDadTK2zJSKOx5hT2vWAS_NCBvNzkWK_6OG2T3YWgoPQf1qmbnERqfaHDCIyAvcbwoZMxo0CVnDt-yVZ_OP6sJj5GTTmD-N71Q6aBWRvc3HKBtSLI1kDwYSMKUNsPk9bBUvUppobZIQoXwPCAvNsmYE93kGuuWKMMzgHAsZTfIAMYUMTQKinm8GumbL4PkjEk8TgKSDubARgDJyIcpTXXpScljmUghoYferWfLVtX_8cGf_I_wU3I38qFIspDFB2S3-7G0zwAQdvlzrwt-A9yaV00 priority: 102 providerName: Springer Nature |
| Title | Effects of short-term fructooligosaccharide intake on equol production in Japanese postmenopausal women consuming soy isoflavone supplements: a pilot study |
| URI | https://link.springer.com/article/10.1186/1475-2891-12-127 https://www.ncbi.nlm.nih.gov/pubmed/24034304 https://www.proquest.com/docview/1437381533 https://www.proquest.com/docview/1459151171 https://www.proquest.com/docview/1663634007 https://pubmed.ncbi.nlm.nih.gov/PMC3848686 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELfo9sILgg1YYFQGIRBIYXX-OA4SQqVsGpWo0EqlvUWJ43QRIe6WFNHPwpflzk3KMsaEVKVSfI7ts32-s8-_I-Q5S7ifeYLZoI0r2xMS5KCQ0k65k_moogoTDObzhB_PvPGpf_rnenTDwOpa0w7jSc0uijc_z1fvYcK_MxNe8APmBT6UFTJ0M2BO0CPb5rQIHfm8zZmCI8Q61EpL3R5aXvOFziLVy2L9t8C-tGJd9aa8cqRqVqqju-ROo2LS4XpM3CO3VLlDdoclmNffV_QFNU6fZjd9h1gfc1XDuwYetKCTFp1_l_xaIxtXVGe0OgMO2SjGaYaAs1oX-VxXscRbW3mqaF7W8TdFdUnV-VIXdLFGkoUPQRIdw5KMoS7pQlfo1g6W-rKC0gz-A5XmGii0hVZ6RfNKZ0X8Q5eKVhhy1OxfVm9pTBd5oWtqAHHvk9nR4dfRsd3EcrAl2N-1ncael3IRKxUrJw2lE_iMc9A31CBQysk8PxExy3yQB4jIwxMeINahC-qOL0OVug_IVgkl7xE6SIMsSF3pu0kCS6sfS5GmYJaJLARdMOEWOWg7L5IN0DnG2ygiY_AIHmF3R9jdEXPgF1jk1SbHYg3ycQPtHoyHKJ6DDI5mUwctVLRK4WGRZzhIIoTVKNFvZw68rKJP05No6LsIXMcx_8uGKNNQKxk31yCgbYjE1aHc71DCvJfd5HYsRu20gdoiUhXq8BZ5uknGnOhLVyq9RBo_BD2PBewGGlBEuQuNgmIerof3hjOI4Oi5A88iQWfgbwgQsbybUuZnBrncFZ7gAnrodTtFLlX9Hwx_9N8Me0xuOyZYSWgzd59s1RdL9QRUxjrpk15wGsBTjFifbA-H4-kY_j8cTr6cwNsRH_XNZkzfSIzfzwNrsw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa27gFeEGzACgMM4iKQojU3x0GaUGGb2l0qtK3S3ozjOG1FiTvSgvpb-C_8Ns5xk9IO0bdJVR7qkzj2OTkX-_g7hLx0ExZmAXcd8Ma1E3AFepAr5aTMy0J0UbktBnPaYa1ucHQZXq6R39VZGEyrrHSiVdSpUbhGvutaDB70Tj6MrhysGoW7q1UJDVmWVkj3LMRYebDjWE9_QghX7LX3gd-vPO_w4OJTyymrDDgKIsOxk8ogSBmXWkvtpbHyotBlDCyhbkRae1kQJly6WQiSilgxLGERovD50FGoYp368Nx1shHgAkqNbHw86Hw-m4d8nMdRtTnKGQwiCmFWYhcTImwlmwVjuJ5J869hWLCM17M2r23dWot4eJfcKV1Z2pzJ3j2ypvNNstXMIYz_NqWvqU0utav2m6S-P9Bj-K-EIR3STlUFYIv8miEoF9RktOhDOOCguaAZAtsaMxz0TAET34egPtV0kI_lV01NTvXVxAzpaIZYCw-CJnoEph9LatKRKTB93ozkpIDeLM4EVfa4KYyFFmZKB4XJhvKHyTUtsLSpXSct3lNJR4OhGVMLvHufdG-Emw9ILYeetwltpFEWpb4K_SQBEx5KxdMUwj-exeBzJqxOdivmCVUCqmNdj6GwgRVnAtktkN3C9eAX1cnb-R2jGZjICtptkAche6DrRffcw0gYo1-41MkLFBKB8B055gf1YC4L0T4_E83QR4A8hve_KYkyA2-lZHncAsaGiF9LlDtLlKBf1HJzJYui1G-F-Ps11snzeTPeiTl7uTYTpAlj8CfdyF1BAw4v82FQ0M3DmXjPZwaRIgO_EdRJtCT4cwJERl9uyQd9i5Du84AzDhx6V30iC6_-nwl_tHqcz8it1sXpiThpd44fk9uerYoSO66_Q2rj7xP9BHzTcfK0VACUfLlpnfMHKqiesw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1tb9MwELbYJk18maADFhhgEAKBFLV5sePwrWJUW2EVokzatyhx7C4ixAWnSPst_Fnu8lKtAyYhVflQn2M7ts_P2efnCHnhZZzpUHguoHHlhkKCHhRSujn3NUOIKppgMKczfnwWTs_ZebfhZntv9_5Isr3TgCxNVT1c5rqd4oIPvTBi8PbYQ8cCz4-2yI5gcQzG1854PJ1P1yaXEHHUH07-Jd_GYrSlU_OnYr6yMl33mrx2dNqsSJM7ZK-DknTc9v1dcktVA7I_rsCM_nZJX9LGubPZNR8Q56hQNfzX0YCWdNaz8A_I7ml3vr5PfrVkxpYaTe0FIHMXNTfVyDFrTFksjE0lXtQqckWLqk6_Kmoqqr6vTEmXLXksvBOS6BRWYYxuSZfGoic7GOcrCwU3lA9UNjc_oVnUmktaWKPL9KepFLUYZbTZsrRvaUqXRWlq2nDg3iNnk_df3h27XfgGV4LJXbt5GoY5F6lSqfLzWPoR8zgHiKFGkVK-DlkmUk8zUAFIwsMzHiG9YQAIh8lY5cF9sl1ByQeEjvJIR3kgWZBlsJqyVIo8B0tM6BjgX8YdMuz7MZEdtzmG2CiTxsYRPMGeT7DnE8-HX-SQ1-scy5bX4wbZAxgaSboAtZuczX00StEQhYdDnuN4SZBJo0JXnQV8S5uczD8nYxYgVx3H_K86IW2gVjLtbj5A25B8a0PycEMSprrcTO6HZdKpGgu1RXIqhO0OebZOxpzoPlcps0IZFgO08yLvBhnAnjyARkExD9qRvv4ySNoYBqPQIdHGHFgLIEn5ZkpVXDRk5YEIBRfQQ2_62XKl6v_44A__R_gp2f10NEk-nsw-PCK3_SZaSex6wSHZrn-s1GPAjHX2pFMMvwGXK2P6 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+short-term+fructooligosaccharide+intake+on+equol+production+in+Japanese+postmenopausal+women+consuming+soy+isoflavone+supplements%3A+a+pilot+study&rft.jtitle=Nutrition+journal&rft.au=Tousen%2C+Yuko&rft.au=Uehara%2C+Mariko&rft.au=Abe%2C+Fumiko&rft.au=Kimira%2C+Yoshifumi&rft.date=2013-09-13&rft.pub=BioMed+Central+Ltd&rft.issn=1475-2891&rft.eissn=1475-2891&rft.volume=12&rft_id=info:doi/10.1186%2F1475-2891-12-127&rft.externalDocID=A534654627 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2891&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2891&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2891&client=summon |